Literature DB >> 206644

Effect of pseudotype on Abelson virus and Kirsten sarcoma virus-induced leukemia.

C D Scher.   

Abstract

Nonproducer cells transformed by Kirsten sarcoma virus (KiSV) or Abelson murine leukemia virus (A-MuLV) were infected with N- or NB-tropic helper viruses to rescue the defective transforming virus. The titer of the transforming viruses was determined on NIH/3T3 fibroblast-like cells and cell-free filtrates of virus stock were inoculated into newborn Fv-1nn mice. Friend, Moloney, and Rauscher group of MuLV (FMR) pseudotypes of KiSV induced an erythroid leukemia efficiently, while an endogenous helper (N35-MuLV) pseudotype of KiSV did not. FMR pseudotypes of A-MuLV induced the Abelson lymphoid leukemia, while the N35-MuLV or a Kirsten leukemia virus (Ki-MuLV) pseudotype did not. Pseudotypes of A-MuLV were used to infect bone marrow cells of Fv-1nn mice in vitro. The FMR pseudotypes transformed bone marrow cells at 40-100-fold higher frequency than the N35-MuLV or Ki-MuLV pseudotypes. Mixing experiments demonstrated that the addition of an effective helper, such as M-MuLV did not enhance lymphoid transformation by ineffective A-MuLV (N35-MuLV). The A-MuLV genome is responsible for hematopoietic cell transformation because a nonproducer clone of lymphoid cells, free of helper virus, was isolated. The data indicates that the pseudotype of A-MuLV determines its ability to transform hematopoietic cells.

Entities:  

Mesh:

Year:  1978        PMID: 206644      PMCID: PMC2184244          DOI: 10.1084/jem.147.4.1044

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  23 in total

1.  ASSAY FOR FRIEND LEUKEMIA VIRUS: RAPID QUANTITATIVE METHOD BASED ON ENUMERATION OF MACROSCOPIC SPLEEN FOCI IN MICE.

Authors:  A A AXELRAD; R A STEEVES
Journal:  Virology       Date:  1964-11       Impact factor: 3.616

2.  A virus-induced disease of mice characterized by erythrocytopoiesis and lymphoid leukemia.

Authors:  F J RAUSCHER
Journal:  J Natl Cancer Inst       Date:  1962-09       Impact factor: 13.506

3.  Effect of the Fv-1 locus on the titration of murine leukemia viruses.

Authors:  P Jolicoeur; D Baltimore
Journal:  J Virol       Date:  1975-12       Impact factor: 5.103

4.  Abelson virus-transformed lymphocytes: null cells that modulate H-2.

Authors:  D M Pratt; J Strominger; R Parkman; D Kaplan; J Schwaber; N Rosenberg; C D Scher
Journal:  Cell       Date:  1977-11       Impact factor: 41.582

5.  Evidence for genetic recombination between endogenous and exogenous mouse RNA type C viruses.

Authors:  J R Stephenson; G R Anderson; S R Tronick; S A Aaronson
Journal:  Cell       Date:  1974-06       Impact factor: 41.582

6.  Lymphosarcoma: virus-induced thymic-independent disease in mice.

Authors:  H T Abelson; L S Rabstein
Journal:  Cancer Res       Date:  1970-08       Impact factor: 12.701

7.  Plaque assay techniques for murine leukemia viruses.

Authors:  W P Rowe; W E Pugh; J W Hartley
Journal:  Virology       Date:  1970-12       Impact factor: 3.616

8.  Friend strain of spleen focus-forming virus: a recombinant between mouse type C ecotropic viral sequences and sequences related to xenotropic virus.

Authors:  D H Troxler; J K Boyars; W P Parks; E M Scolnick
Journal:  J Virol       Date:  1977-05       Impact factor: 5.103

9.  Measurement of the sequence complexity of cloned Moloney murine leukemia virus 60 to 70S RNA: evidence for a haploid genome.

Authors:  H Fan; M Paskind
Journal:  J Virol       Date:  1974-09       Impact factor: 5.103

10.  Murine leukemia virus: high-frequency activation in vitro by 5-iododeoxyuridine and 5-bromodeoxyuridine.

Authors:  D R Lowy; W P Rowe; N Teich; J W Hartley
Journal:  Science       Date:  1971-10-08       Impact factor: 47.728

View more
  18 in total

1.  Identification of an Abelson murine leukemia virus-encoded protein present in transformed fibroblast and lymphoid cells.

Authors:  O N Witte; N Rosenberg; M Paskind; A Shields; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

2.  Abelson murine leukemia virus mutants deficient in kinase activity and lymphoid cell transformation.

Authors:  N E Rosenberg; D R Clark; O N Witte
Journal:  J Virol       Date:  1980-12       Impact factor: 5.103

3.  Virus production by Abelson murine leukemia virus-transformed lymphoid cells.

Authors:  A Shields; N Rosenberg; D Baltimore
Journal:  J Virol       Date:  1979-08       Impact factor: 5.103

4.  Cell transformation and tumor induction by Abelson murine leukemia virus in the absence of helper virus.

Authors:  P L Green; D A Kaehler; R Risser
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

5.  Important role of the long terminal repeat of the helper Moloney murine leukemia virus in Abelson virus-induced lymphoma.

Authors:  P Savard; L DesGroseillers; E Rassart; Y Poirier; P Jolicoeur
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

6.  Thymocyte subsets transformed by Abelson murine leukemia virus.

Authors:  W D Cook
Journal:  Mol Cell Biol       Date:  1985-02       Impact factor: 4.272

7.  The helper virus envelope glycoprotein affects the disease specificity of a recombinant murine leukemia virus carrying a v-myc oncogene.

Authors:  S W Granger; H Fan
Journal:  Virus Genes       Date:  2001-06       Impact factor: 2.332

8.  Recombinant murine retroviruses containing avian v-myc induce a wide spectrum of neoplasms in newborn mice.

Authors:  H C Morse; J W Hartley; T N Fredrickson; R A Yetter; C Majumdar; J L Cleveland; U R Rapp
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

9.  Distinct helper virus requirements for Abelson murine leukemia virus-induced pre-B- and T-cell lymphomas.

Authors:  Y Poirier; P Jolicoeur
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

10.  Friend erythroleukemia antigen. A viral antigen specified by spleen focus-forming virus and differentiation antigen controlled by the Fv-2 locus.

Authors:  R Risser
Journal:  J Exp Med       Date:  1979-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.